- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03361176
Kybella With Triamcinolone
A Randomized, Double-blind, Dose-ranging Trial of Subcutaneous Sodium Deoxycholate Injections With or Without Low Dose Triamcinolone and Low Dose Lidocaine for Reduction of Submental Fat With Reduction of Pain and Swelling
Study Overview
Status
Conditions
Detailed Description
This is a two-site randomized, double-blind comparison trial of Kybella(TM) injections with or without triamcinolone acetate for the reduction of submental fat. 30 subjects will be enrolled into the trial (15 subjects per site). At each site, 5 will be randomized to receive Kybella(TM) injections alone whereas 10 will receive Kybella(TM) plus differing doses of triamcinolone acetate in the following way:
- Group 1 (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
- Group 2 (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle. The final Kybella concentration per vial will be 10mg/1.2mls or 1.6mg per 0.2 cc injection point
The treatment area will be bounded superiorly by a line 1 cm inferior to the mandibular margin, laterally by the sternocleidomastoid muscles, and inferiorly by the hyoid bone. The subjects and evaluating investigator will be blinded to the treatment, thus maintaining double-blind status. By nature of the varying volumes of injection, the treating investigator will be unblinded to the treatment. A series of 3 injection sessions will be performed spaced 4 weeks apart. No lidocaine will be injected prior to injections to prevent further dilution of injected Kybella™ as it will be premixed with Kybella™. Chilling with cold will be the method of pain reduction for needle insertion.
Canfield Vectra 3D imaging will be performed at baseline and final visit (Appendix C) with analysis and calculation of volumetric changes performed at baseline and final visit. Photos will also be taken with the Intellistudio at all other visits. Follow up visits will be performed 3 and 5 days after each injection session to assess for side effect and tolerability profile. After the final injection session, additional follow up visits will be performed at days 90 and 180 to assess for efficacy. Subject weight will be recorded at baseline and at end of study.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92121
- West Dermatology Research Center
-
-
Maryland
-
Hunt Valley, Maryland, United States, 21030
- Maryland Dermatology Laser, Skin and Vein Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Females or Males in good general health age 18 - 65 years of age
- Fitzpatrick skin types I-VI
- Must be willing to give and sign a HIPAA form and informed consent form
- Must be willing and able to comply with all study protocols and schedules
- Must have submental fat graded by the investigator as 2 or 3 using the Clinician-Reported Submental Fat Rating Scale (PR-SMFRS)
- Negative urine pregnancy test prior to each treatment (if applicable)
Female patients will be either of non-childbearing potential defined as:
7.1 Having no uterus 7.2 No menses for at least 12 months. Or; (WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as: 7.3 Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device 7.4 Intrauterine coil 7.5 Bilateral tubal ligation 7.6 Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom) 7.7 Abstinence (If practicing abstinence must agree to use barrier method described above (7.6) if becomes sexually active) 7.8 Vasectomized partner (must agree to use barrier method described above (7.6) if becomes sexually active with unvasectomized partner)
- Males must be willing to be clean shaven for all study visits
- The patient must have had a stable weight (no fluctuation of >15 pounds in a year), diet, and physical activity for the previous 6 months
Exclusion Criteria:
- Pregnancy, currently breast feeding or planning pregnancy for the duration of the trial
- Any UNCONTROLLED systemic disease -a potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study
- Treatment with botulinum toxin injections in the neck or chin area within 6 months before randomization
- Any Scars, unshaven hair, tattoos or jewelry on or near the proposed treatment area
- Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study
- An active dermatitis or open wound in the proposed treatment area
- An active bacterial, fungal, or viral infection in the proposed treatment area
- Pre-existing skin condition to the submental region that may confound evaluation or analysis, at investigator discretion
- Previously treated with subcutaneous sodium deoxycholate to the submental region
- Previously treated with focused ultrasound, radiofrequency, cryolipolysis or liposuction to the submental region within the previous 6 months
- Any other laser, light energy device, or chemical peel treatment to the submental region within the previous 3 months
- Pre-existing neurological or gastrointestinal condition leading to dysphagia, dysphonia or facial nerve palsy
- Pre-existing medical condition other than increased submental fat that may result in increased submental fullness such as but not limited to thyroid enlargement, goiter, cervical lymphadenopathy etc., at investigator discretion
- Must not have a planned fat reduction procedure of any variety to the submental region for the duration of the study
- Must not have planned significant alterations in diet or physical activity that may result in significant fluctuations in weight
- Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control
Control Group (5 patients per site): Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline delivered in up to 50 injections per treatment session.
|
Kybella(TM) alone: 2 mg/cm2 of Kybella(TM) with 0.2 mL of 1% lidocaine with no epinephrine plus 0.2cc saline to the non-TMC group to maintain equal concentrations in each injection so that the final Kybella concentration per vial will be 10mg/1.2mls
or 1.6mg per 0.2 cc injection point will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total maximal dose of up to 100 mg of SDOC.
Other Names:
|
Experimental: w/ Triamcinolone
Experimental Group (10 patients per site): Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate and 0.2 mL of 1% lidocaine with no epinephrine delivered in up to 50 injections per treatment session.
|
Kybella(TM)+TMC at 1.0 mg/mL: 2.0 mL of 2 mg/cm2 of Kybella(TM) will be mixed with 0.2 mL of 10 mg/mL of triamcinolone acetate, 0.2 mL of 1% lidocaine with no epinephrine and then delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of SDOC using a 30 gauge (or smaller) 0.5-inch needle.
The final Kybella concentration per vial will be 10mg/1.2mls
or 1.6mg per 0.2 cc injection point
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Clinician-Reported Submental Fat Rating Scale
Time Frame: 90 Days from Baseline
|
Change in efficacy will be measured from Baseline to 90 days post final treatment using a 5-point Clinician-Reported Submental Fat Rating Scale ranging from Absent (score of 0) to Extreme submental convexity (score of 4)
|
90 Days from Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Clinician-Reported Submental Laxity Rating Scale
Time Frame: 90 days from baseline
|
Laxity will be compared between treatment groups at each post-treatment time point through Day 90 using a 5-Point Clinician Evaluation of Side Effects Scale ranging from None (score of 0) to Severe (score of 4).
|
90 days from baseline
|
Subject Satisfaction Rating Scale
Time Frame: Post-treatment to Day 180
|
Satisfaction will be compared between treatment groups at each post-treatment time point through Day 180 using a 7-point satisfaction scale rating from extremely dissatisfied (score of 0) to extremely satisfied (score of 6).
|
Post-treatment to Day 180
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Obesity
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cholagogues and Choleretics
- Triamcinolone
- Triamcinolone Acetonide
- Triamcinolone hexacetonide
- Triamcinolone diacetate
- Deoxycholic Acid
Other Study ID Numbers
- Kybelladose-2017-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adiposity
-
Johns Hopkins UniversityCompleted
-
Neothetics, IncCompletedSubcutaneous Abdominal AdiposityUnited States
-
University Hospital, BrestCompleted
-
University of SharjahAl Jalila FoundationCompleted
-
University Hospital, Basel, SwitzerlandRigshospitalet, DenmarkCompletedAdipositySwitzerland
-
University of Colorado, DenverNational Institute on Aging (NIA)Not yet recruitingMenopause | Aging | Adiposity | Estrogen DeficiencyUnited States
-
Pennington Biomedical Research CenterLouisiana Clinical and Translational Science CenterTerminatedAdiposity | Menopause Surgical | Estrogen DeficiencyUnited States
-
University of Southern CaliforniaTerminatedAdiposity | Obesity, AbdominalUnited States
-
Brigham and Women's HospitalAmerican Heart AssociationActive, not recruiting
Clinical Trials on Injectable sodium deoxycholate
-
Kythera BiopharmaceuticalsCompleted
-
Kythera BiopharmaceuticalsCompleted
-
University Health Network, TorontoSunnybrook Health Sciences Centre; Queen's University; Heart and Stroke Foundation...Not yet recruitingCardiac Surgery | Chronic Iron Deficiency AnaemiaCanada
-
Goldman, Butterwick, Fitzpatrick and GroffAllerganCompletedFat ReductionUnited States
-
First Affiliated Hospital of Zhejiang UniversityWenzhou Central HospitalUnknownHIV/AIDS | Cryptococcal MeningitisChina
-
Virginia Commonwealth UniversityWithdrawnPain, Postoperative | Pain, ChestUnited States
-
Ain Shams UniversityRecruiting
-
Banaras Hindu UniversityCompleted
-
Pamukkale UniversityCompletedPrimary DysmenorrheaTurkey
-
TTY BiopharmUnknownCryptococcal MeningitisTaiwan